Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
pharmaphorum3d
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
BlackDoctor17h
Essential Tips When Caring For An HIV-Positive Child
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Zacks.com on MSN2d
Gilead, MRK Report Data From Investigational Combination Study for HIV
Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Rolling Out10d
A guide to longevity with HIV after stroke
In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...
Mass. budget includes language expanding access to preventative HIV medications
The measure waives the need for a primary care physician’s prescription for HIV medications like PrEP and Doxy PEP.
El País in English2d
HIV infection in six transplant patients in Brazil points to nepotism and greed of a laboratory
Health authorities in Rio de Janeiro are reviewing samples from 288 donors after discovering that two HIV-positive people ...
The American Journal of Managed Care7d
Financial Burdens of HIV Treatment and HCRU
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...
FierceBiotech3d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
HIV treatment breakthroughs: Namibia's success story
Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...